Track 1: Vascular Dementia and Stroke

Vascular dementia is also called multi-infarct dementia (MID) and vascular intellectual impedance. Dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain. People with Dementia give dynamic subjective hindrance, intensely or subacutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). According to a neurologist, Dementia is the second-most-common form of dementia after Alzheimer's disease (AD). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Dementia can be caused by ischemic or hemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gyrus.       

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 2:  Alzheimers Disease

In Alzheimer's disease, high levels of certain proteins inside and outside brain cells make it hard for brain cells to stay healthy and to communicate with each other. The brain region called the hippocampus is the center of learning and memory in the brain, and the brain cells in this region are often the first to be damaged. That's why memory loss is often one of the earliest symptoms of Alzheimer's. While most changes in the brain that cause dementia are permanent and worsen over time, thinking and memory problems caused by various conditions

• Depression
• Medication side effects
• Excess use of alcohol
• Thyroid problems
• Vitamin deficiencies

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 3: Vascular Cognitive Impairment                                                                                                    

Vascular intellectual disability is a decrease in deduction capacities caused by a malady that harms the mind's veins. The vascular malady may cause intellectual hindrance all alone, and can likewise add to impedances in considering and conduct in a man with another cerebrum illness, for example, Alzheimer’s. Cognitive weakness normally goes with clinical disorders in Alzheimer’s related to the vascular ailment of the mind. In view of developing definitional criteria, the recurrence of subjective weakness inferable from cerebrovascular ailment is hard to decide. Dementia happens in up to 33% of elderly patients with stroke as opposed to an immaculate Dementia disorder.

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 4: Dementia with Lewy Body (DLB)

People with Lewy body dementia have a progressive decline in their memory and ability to think; similar to Alzheimer’s disease. However, the cognitive ability or alertness of a person with Lewy body dementia is more likely to fluctuate from one moment to the next, which is not like Alzheimer’s disease. They also often have visual hallucinations (seeing things that aren’t there) and delusions (believing something that is not true). On the surface, people with Lewy body dementia often have problems with movement that resemble Parkinson’s disease. This is because the same structures of the brain are affected in Lewy body dementia and Parkinson’s disease.

• Causes of Lewy Body Dementia
• Symptoms of Lewy Body Dementia
• Diagnosing Lewy Body
• Dementia Cholinesterase Inhibitors
• Diagnosing dementia (general)
• Treating dementia

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 5:Neurodegenerative Diseases

Neurodegenerative disease primarily affects the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias). Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer’s representing approximately 60-70% of dementia cases.

• Alzheimer’s disease (AD) and other dementias
• Parkinson’s disease (PD) and PD-related disorders
• Prion disease
• Motor neuron diseases (MND)
• Huntington’s disease (HD)
• Spinocerebellar ataxia (SCA)
• Spinal muscular atrophy (SMA)

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 6: Dementia Risk Factors                                                                             

Reasons for Dementia rely on upon territories of cerebrum influenced because of dementia. Vascular dementia is dynamic in nature; one of the most regular kinds of dynamic dementia is Lewy body dementia. There are four essential types of reversible dementia: hypothyroidism, vitamin B12 need, and neurosyphilis and Lyme infection. Head harm, stroke or mind tumor may cause dementia. Age is a standout amongst the most imperative hazard element of Alzheimer’s, 65years surpassing people has more odds of having Dementia. A maturing and hereditary legacy from precursors is out of hand yet other hazard variables, for example, hypertension, hyperlipidemia, hyperthyroidism, liquor use in extensive sums; smoking can be avoided or controlled.T he best-known hazard consider for Alzheimer's is expanding age. Most people with sickness are 65 and more Alzheimer's.

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 7:Prevention of Dementia

Dementia is not a particular illness. It's a general term that portrays an extensive variety of symptoms associated with a decrease in memory or other speculation aptitudes sufficiently extreme to diminish a man's capacity to perform regular activities. Prevention of Dementia is the endeavor to abstain from creating dementia, endeavors to anticipate Dementia incorporate attempting to diminish hazard components for vascular sickness, including diabetes, hypertension, weight, smoking, and physical inertia. In Dementia vascular changes that start in brain areas that play a key role in storing and retrieving information may cause memory loss that looks very much like Alzheimer's disease

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 8: Dementia Stages

Dynamic dementia, which is dementia that deteriorates with time, is the most widely recognized sort. Five phases of dynamic vascular dementia have been laid out. They are a piece of the Clinical Dementia Rating (CDR), which experts use to assess the movement of manifestations in patients with Dementia. Vascular brain changes often coexist with changes linked to other types of dementia, including Alzheimer's disease and dementia with Lewy body’s.T he five phases depict a patient's capacity to perform in six unique zones of discernment and working: introduction, memory, judgment, home and side interests, individual care, and group. The stages incorporate early dementia, Moderate dementia, advanced dementia. 

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 9: Ageing and Dementia  

The precarious increment in neurology the rate and predominance of Dementia parallels a maturing populace crosswise over high, center and low-salary nations. Convenient finding, wellbeing related personal satisfaction and medication revelation for patients living with Dementia, be that as it may, are uniquely inadequate. Likewise with Alzheimer's disease, propelling age is a noteworthy hazard calculates for vascular dementia. To understand this guarantee, inquire about needs, information administration components, and option structures for assent are required. Specifically, coordinated effort between Dementia research and care, and change in the openness of genomic and wellbeing information inside mainstream researchers ought to be advanced crosswise over fringes.

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 10: Advances in Dementia diagnosis

Headway in treatment in Dementia is required in comprehension underlying reasons for dementia. Memory treatment has indicated great consequences for Dementia patients. Dementia is a standout amongst the most exorbitant illness in the world, this treatment is anything but difficult to lead and cheap. Memory treatment utilizes past frequencies and urges patients to compose and clarify past rates which help in keeping up psychological wellness. As misery can be one of the most reasons for Alzheimer's psychotherapy helps such patients colossally. Dementia mind through cloud innovation enables patients in monitoring their conditions and advance to rate, supporting staff and arranging in everyday mind in Dementia. Headway in such treatments utilizing innovation and characteristic treatments will help doctors to treat vascular dementia successfully. New movements have been subject of dementia gatherings and prime wellspring of learning as for dementia, these dementia social events has taken one phase closer to Dementia cure.

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 11: Dementia Care Management

The developing number of Dementia patients prompts both approaches, monetary and wellbeing association imperatives. Numerous social insurance frameworks have created case administration programs with a specific end goal to advance Alzheimer's patients and guardians care and administrations conveyance. Treatment of dementia relies on its cause. On account of most dynamic dementia, including Alzheimer's disease there is no cure and no treatment that moderates or stops its movement. In any case, there are medicating medicines that may briefly enhance side effects. Similar pharmaceuticals used to treat Alzheimer's are among the medications once in a while endorsed to help with side effects of different sorts of dementia. Non-sedate treatments can likewise reduce a few manifestations of Dementia. The increasing number of cognitively impaired older adults who exhibit wandering tendencies raises safety concerns. The purpose of the current study in neurology was to research the State-of-the-Art in wearable technologies for persons with Alzheimer's disease and identify challenges unique to this population and lessons learned. Inclusion criteria specified systems that completed laboratory testing and were commercially available for usage by community-based Alzheimer's family caregivers.

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 12: Dementia Nursing

People with Dementia have different mental element shortfalls that incorporate every memory hindrance, that influences the adaptability to discover new data or review data already learned, and one or extra of the ensuing side effects aphasia, apraxia, agnosia, or official brokenness to such an extent that the mental element shortages adversely affect social or action working with a major decrease in past abilities. People with vascular dementia commonly experience the ill effects of comorbid conditions that extra confuse the mind and block best results. Along these lines, creating caregiving techniques individuals with Dementia is pressing by the neurologist, given this expanding commonness and consequently the related weight that vascular dementia places not just on the people, however on the parental figures, relations, and thusly the assets of the human services framework. Traditional perspectives bearing on geriatric nursing ordinarily paint a picture of the care as being moderate paced certain and less requesting than intense care. Be that as it may, care of the matured, and especially those with Dementia is normally confounded, unusual, and flimsy.      

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 13:Treating Dementia

Early discovery and exact analysis in neurology are critical for the neurologist as Dementia is at any rate halfway preventable.I schemic changes in the cerebrum are irreversible, however, the patient with vascular dementia can exhibit times of solidness or even gentle change. Since stroke is a basic piece of Dementia, the objective is to forestall new strokes. This is endeavored through the decrease of stroke chance components, for example, hypertension, high blood lipid levels, atrial fibrillation, or diabetes mellitus. Meta-examinations have discovered that meds for hypertension are viable at counteractive action of pre-stroke dementia, which implies that hypertension treatment ought to be begun early. Raised lipid levels, including HDL, were found to expand the danger of Alzheimer's disease. Ibuprofen is a medicine that is ordinarily recommended for counteractive action of strokes and heart assaults; it is likewise every now and again given to patients with vascular dementia. The treatment of Dementia is symptomatic. Behavioral and psychiatric disturbances such as agitation, depression, and psychosis are common in Alzheimer's disease. The cerebrovascular disease should be treated by an internist and a neurologist familiar with the management of cerebrovascular disease

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 14: Neuropharmacology

Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other. This article will concentrate on both behavioral and atomic neuropharmacology; the real receptors, particle channels, and neurotransmitters controlled through medication activity and how individuals with a neurological issue advantage from this medication activity.  Molecular neuropharmacology includes the investigation of neurons and their neurochemical collaborations; with the general objective of creating drugs that effect sly affect neurological capacity. Concentrate these collaborations, analysts are creating medications to treat a wide range of neurological issue, including torment, neurodegenerative illnesses, for example, Parkinson's disease and Alzheimer's disease, mental disarrange.

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 14: Novel therapeutics 

Novel therapeutics is a standout amongst the most energizing uses of data preparing frameworks is in diagnostics and treatment by the neurologist. This is not astonishing, given that illness analysis is in its center a data handling undertaking that finishes with a choice. In numerous infections, the conclusion can be performed in singular cells. As the most pervasive type of Dementia around the world, Alzheimer's disease (AD) keeps on being a weight for patients and their families. Also, with the worldwide populace of matured people expanding exponentially, Alzheimer's disease speaks to a critical financial weight to society. The advancement of a compelling methodology for the treatment of Alzheimer's disease (AD) is in this way of significant significance, as flow treatment methodologies are constrained to a neurologist that lessen illness symptomatology without tending to the reasons for sickness.     

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

Track 15: Clinical Trials and Drug Development

Rigorous clinical trials on Dementia drugs are continuing in the USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. The most of drugs are in the second and third phases. Most of the clinical trials are done in specific areas are amyloid beta plaques, the immune system, tau tangles. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. There are many developments are going on in Drug discovery of Dementia as old treatments are unable to stop the progression of Dementia. Most associations share their exploration of new medications for Dementia in Dementia conferences to get higher esteem to their items. This gets to be distinctly gainful to different geriatric doctors to redesign themselves with such medications and progressing possibilities by going to Dementia conferences. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offer positivity to discover new approaches in curing Dementia

• Development of Re-purposed Drugs
• Beta-amyloid Polymerization and Inflammation Inhibitor
• Prevention Trials
• Anticonvulsant Drugs for Treatment
• Vaccine Development against Beta-Amyloid
• Animal Models for Toxicology Studies

Related Vascular Dementia Conferences | Vascular Dementia 2019| Movement Disorders| Neurology Conference

 

Vascular Dementia 2019 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the “ Vascular Dementia and Movement Disorders” which is going to be held during November 6-7, 2019 Yokohama, Japan.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2019 organizing committee look forward to meeting you in Yokohama, Japan.

For more details please visit - https://vascular-dementia.neurologyconference.com/

Dementia is a general term for memory misfortune and other intellectual capacities sufficiently genuine to meddle with everyday life. Alzheimer's illness represents 60 to 80 % of dementia cases.

This gathering will build information, offer help, help learning and enable families and carers to search out relevant administrations for their adored one and to build up the most ideal home condition to help recuperation from this mind-boggling and decimating maladies.

Alzheimer's disease is the most common form of dementia. The proportions of those with different forms of dementia can be broken down as follows:

Alzheimer's disease: 62%

Vascular dementia: 17%

Mixed dementia: 10%

Lewy-body dementia: 4%

Frontotemporal dementia: 2%

Parkinson's dementia: 2%

Other: 3%

Why attend???

According to WHO, 47.5 million people have dementia and every year 7.7 million new cases are appearing. By 2030 total cases of dementia is projected to be 75.6 million and almost triple by 2050 to 135.5 million. Alzheimer’s disease contributes 60-70 % of cases in dementia and the second most common condition of dementia is vascular dementia which contributes 20% of cases all over the world. The total estimated cost of dementia is 818 billion US $ in 2015.

With members from around the world focused on learning about various Alzheimer’s disease and how to prevent disorders. This is your best opportunity to reach the largest assemblage of participants from the entire world.

At the Dementia conferences and from the eminent people speech, you can update your knowledge about the current situation of Dementia research and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Dementia fields are hallmarks of this conference.

From every corner of the world, someone develops dementia every 3 seconds. This was an estimated value at 46.8 million people worldwide living with dementia in 2015 and the number is expected to be close to 50 million people in 2017. This number may double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Mostly it is observed to be increased in developing countries. For now, 58% of people with dementia are living in low and middle-income countries, maybe, by 2050 this can rise to 68%.

Worldwide results of current meta-analysis reveal 44 million people (worldwide) suffered from Vascular dementia during 2010 and expected to double every 20 years, to the number 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 percent of all people with low or middle incomes were with dementia lived in countries. This proportion anticipated an increase to 63 percent in 2030 and 71 percent in 2050. 

Vascular Dementia is most widely considered to be the second common cause of Alzheimer's disease, accounting for 10 % of cases. Many experts believe vascular dementia remains less diagnosed for Alzheimer's disease, even the disease is common.

Alzheimer's Research UK at present funds 150 research projects across the UK and focusing on developing stages which have been committed nearly £40million to dementia research.

Their research focus is on the improvement of the quality of life already living with Alzheimer’s disease and also other forms of dementia.

Vascular Dementia 2019 provides a good platform where everyone will be sure having a meaningful experience with scholars, experts across the globe. The members of Vascular Dementia 2019 wishes meeting you in Yokohama, Japan

Why in Japan?

With one in five elderly Japanese predicted to have dementia by 2025, entire communities are working to improve the lives of older citizens and more 4.6 million people are living with dementia. And this number is expected to rise significantly as the population ages. Worldwide, at least 44 million people are living with dementia.

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This numbers will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle-income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbors.

Major Dementia and Alzheimer’s Societies and Associations around Globe.

            Alzheimer's Australia

            Alzheimer Society of Bangladesh

            Alzheimer's Association

            American Academy of Neurology

            European Neurological Societies

            Foundation Alzheimer Aruba (FAA)

            Spanish Society of Neurology

            Major Neurological Associations in Italy

            Hilarescere Foundation in Italy

            Alzheimer Support Group

            Southern Clinical Neurological Society

            ESNR European Society of Neuroradiology

            Alzheimer Austria

            Alzheimer's disease in Chinese 

            Alzheimer's Society

            British brain tumor association     

 Top Neuroscience Universities in Japan     

                  Aino University

                  Osaka Kawasaki Rehabilitation University

                  Hagoromo International University

                  Hannan University

                  Heian Jogakuin-St. Agnes'-University

                  Kansai Medical University

                  Kinki University

                  Kwansei Gakuin University, Osaka-Umeda

                  Morinomiya University of Medical Sciences

                  Soai University

                  Tokiwakai Gakuen University

                  Osaka University

                  Okinawa Institute of Science and Technology

                  Keio University

                  Nagoya University

Top Neuroscience Universities in Globe:

                  Dalhousie University

                  Leiden University

                  Temple University USA

                  University Oklahoma

                  University of Bristol

                  Florida International University

                  University of Edinburgh

                  University of Milan

                  University of Nottingham

                  Cardiff University

                  University of Toronto

                  University Sheffield

                  University California

                  University of Amsterdam 

                  Karolinska Institute

                  University of Gothenburg

Hospital Associated with Neuroscience                   

                 Yokohama Rosai Hospital 

                  Saiseikai Yokohamashi Tobu Hospital

                  Japan bangladesh friendship hospital

                  Ueda Surgery Hospital

                  Yamaguchi university hospital

                  Shonan kamakura general hospital

                   Keiyu Hospital                

Companies Associated with Neuroscience in Japan

                   Pfizer

                   GlaxoSmithKline

                   Solvay of Belgium

                   Fujisawa Pharmaceutical

                   Eli Lilly

                   Forest Laboratories 

                   Wyeth Pharmaceuticals

                   Organon International

 

                  

Vascular Dementia 2019 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the “ Vascular Dementia and Movement Disorders” which is going to be held during November 6-7, 2019 Yokohama, Japan.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2019 organizing committee look forward to meeting you in Yokohama, Japan.

For more details please visit - https://vascular-dementia.neurologyconference.com/

Dementia is a general term for memory misfortune and other intellectual capacities sufficiently genuine to meddle with everyday life. Alzheimer's illness represents 60 to 80 % of dementia cases.

This gathering will build information, offer help, help learning and enable families and carers to search out relevant administrations for their adored one and to build up the most ideal home condition to help recuperation from this mind-boggling and decimating maladies.

Alzheimer's disease is the most common form of dementia. The proportions of those with different forms of dementia can be broken down as follows:

Alzheimer's disease: 62%

Vascular dementia: 17%

Mixed dementia: 10%

Lewy-body dementia: 4%

Frontotemporal dementia: 2%

Parkinson's dementia: 2%

Other: 3%

Why attend???

According to WHO, 47.5 million people have dementia and every year 7.7 million new cases are appearing. By 2030 total cases of dementia is projected to be 75.6 million and almost triple by 2050 to 135.5 million. Alzheimer’s disease contributes 60-70 % of cases in dementia and the second most common condition of dementia is vascular dementia which contributes 20% of cases all over the world. The total estimated cost of dementia is 818 billion US $ in 2015.

With members from around the world focused on learning about various Alzheimer’s disease and how to prevent disorders. This is your best opportunity to reach the largest assemblage of participants from the entire world.

At the Dementia conferences and from the eminent people speech, you can update your knowledge about the current situation of Dementia research and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Dementia fields are hallmarks of this conference.

From every corner of the world, someone develops dementia every 3 seconds. This was an estimated value at 46.8 million people worldwide living with dementia in 2015 and the number is expected to be close to 50 million people in 2017. This number may double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Mostly it is observed to be increased in developing countries. For now, 58% of people with dementia are living in low and middle-income countries, maybe, by 2050 this can rise to 68%.

Worldwide results of current meta-analysis reveal 44 million people (worldwide) suffered from Vascular dementia during 2010 and expected to double every 20 years, to the number 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 percent of all people with low or middle incomes were with dementia lived in countries. This proportion anticipated an increase to 63 percent in 2030 and 71 percent in 2050. 

Vascular Dementia is most widely considered to be the second common cause of Alzheimer's disease, accounting for 10 % of cases. Many experts believe vascular dementia remains less diagnosed for Alzheimer's disease, even the disease is common.

Alzheimer's Research UK at present funds 150 research projects across the UK and focusing on developing stages which have been committed nearly £40million to dementia research.

Their research focus is on the improvement of the quality of life already living with Alzheimer’s disease and also other forms of dementia.

Vascular Dementia 2019 provides a good platform where everyone will be sure having a meaningful experience with scholars, experts across the globe. The members of Vascular Dementia 2019 wishes meeting you in Yokohama, Japan

Why in Japan?

With one in five elderly Japanese predicted to have dementia by 2025, entire communities are working to improve the lives of older citizens and more 4.6 million people are living with dementia. And this number is expected to rise significantly as the population ages. Worldwide, at least 44 million people are living with dementia.

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This numbers will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle-income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbors.

Major Dementia and Alzheimer’s Societies and Associations around Globe.

            Alzheimer's Australia

            Alzheimer Society of Bangladesh

            Alzheimer's Association

            American Academy of Neurology

            European Neurological Societies

            Foundation Alzheimer Aruba (FAA)

            Spanish Society of Neurology

            Major Neurological Associations in Italy

            Hilarescere Foundation in Italy

            Alzheimer Support Group

            Southern Clinical Neurological Society

            ESNR European Society of Neuroradiology

            Alzheimer Austria

            Alzheimer's disease in Chinese 

            Alzheimer's Society

            British brain tumor association     

 Top Neuroscience Universities in Japan     

                  Aino University

                  Osaka Kawasaki Rehabilitation University

                  Hagoromo International University

                  Hannan University

                  Heian Jogakuin-St. Agnes'-University

                  Kansai Medical University

                  Kinki University

                  Kwansei Gakuin University, Osaka-Umeda

                  Morinomiya University of Medical Sciences

                  Soai University

                  Tokiwakai Gakuen University

                  Osaka University

                  Okinawa Institute of Science and Technology

                  Keio University

                  Nagoya University

Top Neuroscience Universities in Globe:

                  Dalhousie University

                  Leiden University

                  Temple University USA

                  University Oklahoma

                  University of Bristol

                  Florida International University

                  University of Edinburgh

                  University of Milan

                  University of Nottingham

                  Cardiff University

                  University of Toronto

                  University Sheffield

                  University California

                  University of Amsterdam 

                  Karolinska Institute

                  University of Gothenburg

Hospital Associated with Neuroscience                   

                 Yokohama Rosai Hospital 

                  Saiseikai Yokohamashi Tobu Hospital

                  Japan bangladesh friendship hospital

                  Ueda Surgery Hospital

                  Yamaguchi university hospital

                  Shonan kamakura general hospital

                   Keiyu Hospital                

Companies Associated with Neuroscience in Japan

                   Pfizer

                   GlaxoSmithKline

                   Solvay of Belgium

                   Fujisawa Pharmaceutical

                   Eli Lilly

                   Forest Laboratories 

                   Wyeth Pharmaceuticals

                    Organon International